Sep 30th, 2022 - STOCKHOLM — Recent study results confirm that two agents from the sodium-glucose cotransporter 2 (SGLT2) inhibitor class can significantly cut the incidence of adverse cardiovascular events in patients with heart failure with reduced ejection fraction (HFpEF), a disease especially common in people with type 2 diabetes, obesity, or both. And findings from secondary analyses of the studies ― incl...

Sep 30th, 2022 - STOCKHOLM, Sweden — Enterovirus infection appears to be strongly linked to both type 1 diabetes and islet cell autoantibodies, new research suggests. The strength of the relationship, particularly within the first month of type 1 diabetes diagnosis, "further supports the rationale for development of enterovirus-targeted vaccines and antiviral therapy to prevent and reduce the impact of type 1 d...

Sep 29th, 2022 - STOCKHOLM, Sweden — The investigational once-weekly insulin icodec (Novo Nordisk) significantly reduces A1c without increasing hypoglycemia in people with type 2 diabetes, the first Phase 3 data of such an insulin formulation suggest. The data are from one of six trials in the company's ONWARDS program. "Once-weekly insulin may redefine diabetes management," enthused Athena Philis-Tsimikas, MD,...

Sep 28th, 2022 - STOCKHOLM, Sweden — Whether "insulin-free type 2 diabetes" is either "coming" or "nonsense" was the topic of a debate at the recent European Association for the Study of Diabetes 2022 Annual Meeting. Bruce H.R. Wolffenbuttel, MD, PhD, argued the "nonsense" view, given the heterogeneity and progressive nature of type 2 diabetes, while Apostolos Tsapas, MD, PhD, expressed confidence that newer ap...

Sep 28th, 2022 - Adding community health workers (CHW) to a primary care setting was linked with improved type 2 diabetes management in a safety-net population, new research indicates. The researchers, led by Robert L. Ferrer, MD, MPH, with the department of family and community medicine at the University of Texas Health Science Center, San Antonio, enrolled 986 people in a Latino, inner-city cohort in primary ...

Sep 27th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. STOCKHOLM, Sweden — It remains inconclusive whether SARS-CoV-2 infection predisposes children and adolescents to a higher risk of type 1 diabetes. Data from two new studies presented last week, and a research letter just published, add to the growing body of knowledge on the subject, but still c...

Sep 27th, 2022 - This transcript has been edited for clarity. I'm pleased to give an update on the UK Prospective Diabetes Study (UKPDS). This is the longest-running follow-up of a randomized controlled trial in type 2 diabetes. Those familiar with it may remember that the 20-year trial randomized patients to intensive blood glucose control with sulfonylurea/insulin, or in overweight patients, to metformin, com...

Sep 26th, 2022 - STOCKHOLM, Sweden — Weight loss should be a co-primary management goal for type 2 diabetes in adults, according to a new comprehensive joint consensus report from the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA). And while metformin is still recommended as first-line therapy for patients with type 2 diabetes with no other comorbidities, the s...

Sep 23rd, 2022 - This transcript has been edited for clarity. Miriam E. Tucker: I'm with Professor Boris Mankovsky, who's the president of the Ukrainian Diabetology Association. We spoke back in March just after the invasion. At that time, things were bad in terms of getting supplies. You had donated supplies, but they weren't getting to where they needed to go. What's the situation like now? Boris Mankovsky, M...

Sep 23rd, 2022 - STOCKHOLM, Sweden — Adding fenofibrate to a statin was associated with an 11% lower risk of diabetic retinopathy progression in patients with type 2 diabetes, new study data show. The drug combination was also found to reduce the risk of intravitreous injection therapy by 22%, a novel observation. "This finding is not evident from previous clinical trials, where intravitreous injectables were n...

Sep 22nd, 2022 - STOCKHOLM, Sweden — The number of people living with type 1 diabetes worldwide is expected to double by 2040, with most new cases among adults living in low- and middle-income countries, new modeling data suggest. The forecast, developed from available data collected in the newly established open-source Type 1 Diabetes Index, provides estimates for type 1 diabetes prevalence, incidence, associa...

Sep 22nd, 2022 - Long-term A1c from the time of type 1 diabetes diagnosis strongly predicts the development of severe retinopathy and nephropathy, new data suggest. "[Weighted] HbA1c followed from diagnosis is a very strong biomarker for pan-retinal laser-treated diabetic retinopathy (PDR) and nephropathy, [and] the prevalence of both is still increasing 32 years after diagnosis," say Hans J. Arnqvist, MD, and ...

Sep 22nd, 2022 - STOCKHOLM, Sweden — Shivering upon repeated short exposures to cold improves glucose tolerance, decreases fasting blood glucose and lipid levels, and markedly reduces blood pressure, show new study results in adults with obesity and overweight. Presenting the preliminary findings at this year's European Association for the Study of Diabetes (EASD) Annual Meeting, Adam Sellers, a PhD student fro...

Sep 21st, 2022 - STOCKHOLM, Sweden — Esmolol hydrochloride gel (Galnobax, NovoLead) appears to be a safe and effective novel topical treatment option for diabetic foot ulcers, according to results from a new trial of the drug, which is widely available as a generic and is inexpensive. Of note, the proportion of participants achieving target ulcer closure at 12 weeks with esmolol (plus standard of care) was arou...

Sep 21st, 2022 - STOCKHOLM, Sweden — The beneficial effects of the duodenal jejunal bypass liner (EndoBarrier, GI Dynamics) may outweigh the risks for some patients with type 2 diabetes, new data suggest.   The EndoBarrier, a 60-cm implantable sleeve, is endoscopically placed into the first part of the small intestine, creating a physical barrier between receptors in the intestinal wall and food. The mechanism ...

Sep 21st, 2022 - The GLP-1 agonist liraglutide (Victoza, Novo Nordisk) was the overall winner compared with three other diverse agents for treating patients with type 2 diabetes already maintained on metformin. But while liraglutide performed better than insulin glargine, sitagliptin, and glimepiride, the randomized, multicenter study of 5047 patients fell short of being the last word. In part, that's because t...

Sep 20th, 2022 - HealthDay News — Among women with gestational diabetes mellitus (GDM), a joint effect of maternal obesity and excessive weight gain appears to be associated with an increased risk for attention-deficit/hyperactivity disorder (ADHD) in offspring, according to a study published online in the Journal of Clinical Endocrinology & Metabolism. Verónica Perea, MD, PhD, from Hospital Universitari Mútua ...

Sep 20th, 2022 - Stockholm, Sweden — Higher consumption of whole grains, fish, fiber, and omega-3 polyunsaturated fatty acids reduces deaths from all causes in people with type 2 diabetes, show new data. Results from the systematic review and meta-analysis were presented here at this year's European Association for the Study of Diabetes (EASD) Annual Meeting by lead author Janett Barbaresko, PhD, a researcher f...

Sep 20th, 2022 - STOCKHOLM – New evidence continues to show that alternative measures of adiposity than body mass index, such as waist-to-hip ratio, work better for predicting the risk a person with overweight or obesity faces from their excess weight. A direct comparison of waist-to-hip ratio (WHR), body mass index (BMI), and fat mass index (FMI) in a total of more than 380,000 United Kingdom residents include...

Sep 20th, 2022 - In a small cross-sectional study of 10- to 16-year-old girls with and without type 1 diabetes, both groups were equally physically active, based on their replies to the bone-specific physical activity questionnaire (BPAQ). However, among the more sedentary girls (with BPAQ scores below the median), those with type 1 diabetes had worse markers of bone health in imaging tests compared to the girl...